Pieris Pharmaceuticals, Inc. – NASDAQ:PIRS

Pieris Pharmaceuticals stock price today

$13.26
-0.33
-2.5%
Financial Health
0
1
2
3
4
5
6
7
8
9

Pieris Pharmaceuticals stock price monthly change

+98.54%
month

Pieris Pharmaceuticals stock price quarterly change

+98.54%
quarter

Pieris Pharmaceuticals stock price yearly change

+9614.29%
year

Pieris Pharmaceuticals key metrics

Market Cap
17.95M
Enterprise value
30.01M
P/E
-2.11
EV/Sales
0.73
EV/EBITDA
-0.57
Price/Sales
1.38
Price/Book
2.01
PEG ratio
-0.06
EPS
-12.73
Revenue
40.92M
EBITDA
12.02M
Income
-16.25M
Revenue Q/Q
-97.26%
Revenue Y/Y
142.89%
Profit margin
-120.03%
Oper. margin
-155.86%
Gross margin
9.11%
EBIT margin
-155.86%
EBITDA margin
29.37%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Pieris Pharmaceuticals stock price history

Pieris Pharmaceuticals stock forecast

Pieris Pharmaceuticals financial statements

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): Profit margin
Jun 2023 20.05M 3.97M 19.83%
Sep 2023 19.52M -10.75M -55.08%
Dec 2023 1.29M -4.58M -352.89%
Mar 2024 53K -4.89M -9230.19%
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): Analyst Estimates
2025 7M -26.29M -375.7%
2026 48.93M -27.91M -57.06%
  • Analysts Price target

  • Financials & Ratios estimates

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): Debt to assets
Jun 2023 87544000 47.04M 53.74%
Sep 2023 59376000 28.86M 48.62%
Dec 2023 38680000 11.92M 30.82%
Mar 2024 29497000 7.53M 25.54%
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): Cash Flow
Jun 2023 -13.43M -1.36M 19.78M
Sep 2023 -9.72M -1.98M 0
Dec 2023 -19.66M 3.44M 14K
Mar 2024 -6.99M 9M 0

Pieris Pharmaceuticals alternative data

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): Employee count
Aug 2023 127
Sep 2023 127
Oct 2023 127
Nov 2023 127
Dec 2023 127
Jan 2024 127
Feb 2024 127
Mar 2024 127
Apr 2024 127
May 2024 46
Jun 2024 46
Jul 2024 46

Pieris Pharmaceuticals other data

46.16% -4.51%
of PIRS is owned by hedge funds
34.21M -3.13M
shares is hold by hedge funds

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): Insider trades (number of shares)
Period Buy Sel
Aug 2024 6001 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ADAR1 CAPITAL MANAGEMENT, LLC 10 percent owner
Common Stock 2,243 $15.88 $35,623
Purchase
ADAR1 CAPITAL MANAGEMENT, LLC 10 percent owner
Common Stock 757 $15.88 $12,023
Purchase
ADAR1 CAPITAL MANAGEMENT, LLC 10 percent owner
Common Stock 3,000 $14.89 $44,679
Purchase
GERAGHTY JAMES A director
Series F Preferred Stock, par value $0.001 per share 1 $1 $1
Purchase
KIRITSY CHRISTOPHER P director
Common Stock 10,000 $0.85 $8,500
Purchase
DEMUTH TIM officer: Chief Medical Officer
Common Stock 6,000 $1.71 $10,260
Option
OLWILL SHANE officer: Chief Development Offi..
Stock Option (right to buy) 38,400 $1.52 $58,368
Sale
OLWILL SHANE officer: Chief Development Offi..
Common Stock 9,200 $5 $46,000
Sale
OLWILL SHANE officer: Chief Development Offi..
Common Stock 29,200 $5.15 $150,380
Option
OLWILL SHANE officer: Chief Development Offi..
Common Stock 38,400 $1.52 $58,368
Wednesday, 20 November 2024
businesswire.com
Tuesday, 15 October 2024
globenewswire.com
Thursday, 3 October 2024
globenewswire.com
Tuesday, 3 September 2024
businesswire.com
Friday, 16 August 2024
prnewswire.com
globenewswire.com
Wednesday, 14 August 2024
prnewswire.com
Tuesday, 13 August 2024
globenewswire.com
Wednesday, 24 July 2024
prnewswire.com
investorplace.com
Friday, 19 April 2024
accesswire.com
Wednesday, 27 March 2024
accesswire.com
Monday, 25 September 2023
Zacks Investment Research
Monday, 28 August 2023
PennyStocks
Friday, 25 August 2023
PennyStocks
Thursday, 24 August 2023
PennyStocks
Wednesday, 23 August 2023
Zacks Investment Research
Zacks Investment Research
Tuesday, 22 August 2023
PennyStocks
Wednesday, 16 August 2023
Zacks Investment Research
Wednesday, 19 July 2023
Zacks Investment Research
Friday, 23 June 2023
Zacks Investment Research
Friday, 2 June 2023
Accesswire
Wednesday, 17 May 2023
Seeking Alpha
Friday, 12 May 2023
PennyStocks
Thursday, 11 May 2023
PennyStocks
Wednesday, 10 May 2023
Zacks Investment Research
Tuesday, 2 May 2023
Accesswire
Wednesday, 29 March 2023
Seeking Alpha
Zacks Investment Research
  • What's the price of Pieris Pharmaceuticals stock today?

    One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $13.26.

  • When is Pieris Pharmaceuticals's next earnings date?

    Unfortunately, Pieris Pharmaceuticals's (PIRS) next earnings date is currently unknown.

  • Does Pieris Pharmaceuticals pay dividends?

    No, Pieris Pharmaceuticals does not pay dividends.

  • How much money does Pieris Pharmaceuticals make?

    Pieris Pharmaceuticals has a market capitalization of 17.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 65.28% to 42.81M US dollars.

  • What is Pieris Pharmaceuticals's stock symbol?

    Pieris Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PIRS".

  • What is Pieris Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Pieris Pharmaceuticals?

    Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Pieris Pharmaceuticals's key executives?

    Pieris Pharmaceuticals's management team includes the following people:

    • Mr. Stephen S. Yoder Chief Executive Officer, Pres & Director(age: 49, pay: $730,130)
    • Dr. Hitto Kaufmann Ph.D. Senior Vice President & Chief Scientific Officer(age: 54, pay: $458,680)
    • Mr. Thomas Bures Senior Vice President & Chief Financial Officer(age: 51, pay: $360,510)
  • How many employees does Pieris Pharmaceuticals have?

    As Jul 2024, Pieris Pharmaceuticals employs 46 workers, which is 64% less then previous quarter.

  • When Pieris Pharmaceuticals went public?

    Pieris Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 2 Jan 2015.

  • What is Pieris Pharmaceuticals's official website?

    The official website for Pieris Pharmaceuticals is pieris.com.

  • Where are Pieris Pharmaceuticals's headquarters?

    Pieris Pharmaceuticals is headquartered at 255 State Street, Boston, MA.

  • How can i contact Pieris Pharmaceuticals?

    Pieris Pharmaceuticals's mailing address is 255 State Street, Boston, MA and company can be reached via phone at 857 246 8998.

Pieris Pharmaceuticals company profile:

Pieris Pharmaceuticals, Inc.

pieris.com
Exchange:

NASDAQ

Full time employees:

46

Industry:

Biotechnology

Sector:

Healthcare

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

255 State Street
Boston, MA 02109

CIK: 0001583648
ISIN: US7207951036
CUSIP: 720795103